Education
About Us
Working with TipRanks
Follow Us
Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
$5.02
-$0.24(-10.17%)
At close: 4:00 PM EST
$5.02
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)990.33K
Market Cap
$324.56M
Enterprise Value$57.42M
Total Cash (Recent Filing)$172.83M
Total Debt (Recent Filing)$3.82M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
May 12, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding64,652,920
10 Day Avg. Volume1,634,167
30 Day Avg. Volume990,327
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-72.61
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$17.00Price Target Upside238.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data — Survival UpdateSurvival update for atebimetinib combined with chemotherapy could clarify the therapy's patient benefits and drive investor confidence if results show improved overall survival.
Financial PositionA reported cash position that supports ongoing operations reduces financing pressure and lowers the risk of shareholder dilution while enabling continued trial progress.
Regulatory And Development ProgressAdvancement of the pivotal Phase 3 MAPKeeper trial after alignment with regulatory authorities supports a defined development pathway that could validate commercial prospects.
Bears Say
Competitive DifferentiationUncertainty about how atebimetinib differs clinically from a competing therapy undermines investor confidence and could limit upside until clear differentiation is demonstrated.
Efficacy Confirmation RiskSimilar progression-free survival to the competing therapy means overall survival results will be necessary to demonstrate a meaningful clinical advantage, increasing trial risk and investor caution.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $324.56M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is May 12, 2026 which is in 50 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on Mar 06, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.312 by $0.132.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.28.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,652,920 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.312. Following the earnings report the stock price went up 7.028%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (238.65% Upside)
$17.00 (238.65% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $234.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
204.24%
12-Months-Change
Fundamentals
Return on Equity
-43.33%
Trailing 12-Months
Asset Growth
340.08%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.View all IMRX earnings summariesIMRX Stock 12 Month Forecast
Average Price Target
$17.00
▲(238.65% Upside)
Technical Analysis
Ownership Overview
9.49% Insiders
15.53% Mutual Funds
13.89% Other Institutional Investors
52.64% Public Companies and
Individual Investors